MicroRNA study for small testicular or post-chemo masses
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This study looks at tiny molecules called microRNAs in the blood of people with either small testicular tumors (less than 2 cm) or leftover lymph node masses after chemotherapy for testicular cancer. The goal is to see if these microRNAs can help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- If you have a testicular lesion: it must be smaller than 2 cm and involve less than 30% of the testicle.
- If you have a post-chemotherapy mass: it must be a lymph node in the abdomen larger than 1 cm (for non-seminoma) or larger than 3 cm (for seminoma).
- Your blood tumor markers must be negative (normal).
- You must be eligible for either testis-sparing surgery or retroperitoneal lymph node dissection.
- You must give your informed consent to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny genetic signals called microRNAs to see if they can help identify or track testicular cancer. It may help doctors recognize testicular cancer more accurately and decide what to do next.
This trial tests whether a blood test called miRNA-371 can detect active germ cell tumors in patients who have had surgery or are being watched. It may help guide treatment decisions without needing extra biopsies or scans.
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
This study looks at tiny particles (microRNA) and cancer cells in the blood of people with cancer who are getting immunotherapy. It aims to find patterns that might help doctors better understand how the treatment is working.
This study looks at tiny blood molecules called microRNAs to see if they can help diagnose non-Hodgkin's lymphoma. If you are newly diagnosed and have no other cancers, your blood test results may be compared to known patterns to improve diagnosis.
This study is looking at a new marker called miRNA371 in people newly diagnosed with germ cell tumors. The goal is to see if it can help predict relapse and guide treatment decisions.
Hear when a new Testicular Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.